Full REMAIN-1 pivotal study enrollment anticipated in summer 2025 ...

Eli Lilly said on Tuesday it had sued two mass compounders for selling unapproved products that contain tirzepatide, the main ...

Affordable and alternative versions of popular weigh loss drugs, like Ozempic and Wegovy, may no longer be available.

Lexicon Pharmaceuticals, headquartered in The Woodlands, announced it will exclusively license its drug LX9851 to the maker ...

Whether you’re on a weight loss journey of your own or not, you probably haven’t been able to avoid hearing about the sudden ...

Starting next month, the Food and Drug Administration will restrict who can make and sell popular weight-loss medications known as  GLP-1s.

Novo Nordisk's Phase 3b STRIDE trial shows Ozempic improves walking distance in peripheral artery disease, while the SOUL ...